Biomarker analysis of on-treatment and at progression biopsies from BRIM7 - a phase 1B trial of combined vemurafenib and cobimetinib treatment in BRAF V600 mutated melanoma

Yibing Yan; Grant McArthur; Omid Hamid; Igor Puzanov; Rene Gonzalez; Thomas Gajewski; Yulei Wang; Matthew Wongchenko; Nicholas Choong; Antoni Ribas

首页> 外文期刊>Journal of Translational Medicine >Biomarker analysis of on-treatment and at progression biopsies from BRIM7 - a phase 1B trial of combined vemurafenib and cobimetinib treatment in BRAF V600 mutated melanoma

【24h】

Biomarker analysis of on-treatment and at progression biopsies from BRIM7 - a phase 1B trial of combined vemurafenib and cobimetinib treatment in BRAF V600 mutated melanoma

机译：从BRIM7进行的活检和进行中活检的生物标志物分析-维拉非尼和Cobimetinib联合治疗BRAF V600突变的黑色素瘤的1B期试验

获取原文

获取外文期刊封面封底 >>

开具论文收录证明 >>

文献代查 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《Journal of Translational Medicine》 |2014年第1期|共页
作者
Yibing Yan; Grant McArthur; Omid Hamid; Igor Puzanov; Rene Gonzalez; Thomas Gajewski; Yulei Wang; Matthew Wongchenko; Nicholas Choong; Antoni Ribas;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种
中图分类心脏、血管（循环系）疾病;
关键词

相似文献

外文文献

1. Updated results and correlative FDG-PET analysis of a phase IB study of vemurafenib and cobimetinib (MEK inhibitor [GDC-0973]), in advanced BRAF V600 - mutated melanoma (BRIM7) [J] . Igor Puzanov, Grant McArthur, Rene Gonzalez, Journal of Translational Medicine . 2014,第SUPPLEMENTa1期

机译：vemurafenib和cobimetinib（MEK抑制剂[GDC-0973]）在晚期BRAF V600突变的黑色素瘤（BRIM7）的IB期IB研究中的更新结果和相关的FDG-PET分析
2. Atezolizumab, vemurafenib, and cobimetinib as first-line treatment for unresectable advanced BRAF(V600) mutation-positive melanoma (IMspire150): primary analysis of the randomised, double-blind, placebo-controlled, phase 3 trial [J] . Gutzmer Ralf, Stroyakovskiy Daniil, Gogas Helen, The Lancet . 2020,第10240期

机译：Atezolizumab，Vemurafenib和Cobimetinib作为无可缩放的先进BRAF（V600）突变阳性黑素瘤（IMSPIRE150）的一线治疗：对随机，双盲，安慰剂控制，第3期试验的主要分析
3. Cobimetinib combined with vemurafenib in advanced BRAF(V600)-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial [J] . Ascierto Paolo A., McArthur Grant A., Dreno Brigitte, The lancet oncology . 2016,第9期

机译：Cobimetinib与vemurafenib联合用于晚期BRAF（V600）突变型黑色素瘤（coBRIM）：一项随机，双盲，3期临床试验的最新疗效结果
4. Development of Nanoliposomes for the Treatment of Braf V600e Mutated Parent and Vemurafenib-Resistant Melanoma [D] . Fu, Yige. 2021

机译：用于治疗BRAF V600E突变父母和vemureafenib抗性黑素瘤的纳米脂质体的研制
5. Biomarker analysis of on-treatment and at progression biopsies from BRIM7 - a phase 1B trial of combined vemurafenib and cobimetinib treatment in BRAF V600 mutated melanoma [O] . Yibing Yan, Grant McArthur, Omid Hamid, 2014

机译：BRIM7进行中活检和进行中活检的生物标志物分析-维拉非尼和Cobimetinib联合治疗BRAF V600突变的黑色素瘤的1B期试验
6. Biomarker analysis of on-treatment and at progression biopsies from BRIM7 - a phase 1B trial of combined vemurafenib and cobimetinib treatment in BRAF V600 mutated melanoma [O] . Yibing Yan, Grant McArthur, Omid Hamid, 2014

机译：从BRIM7进行的活检和进行中活检的生物标记分析-维拉非尼和Cobimetinib联合治疗BRAF V600突变的黑色素瘤的1B期试验

Biomarker analysis of on-treatment and at progression biopsies from BRIM7 - a phase 1B trial of combined vemurafenib and cobimetinib treatment in BRAF V600 mutated melanoma

著录项

相似文献

相关主题

期刊订阅